GP531
phase 2drug program · high
Treat acute decompensated heart failure by improving myocardial bioenergetics in conditions involving mitochondrial dysfunction; broader company focus includes heart failure with reduced ejection fraction, heart failure with preserved ejection fraction of specific etiology, and neurological/metabolic disorders involving mitochondrial dysfunction.
Infusion therapy described as an AMP-activated protein kinase agonist targeting mitochondrial dysfunction and improving myocardial bioenergetics.
Described as a Phase 2 infusion therapy for acute decompensated heart failure.